To extend our finding that mbIL12 signaling enhances regional to systemic disease targeting by CAR T cells, we used the patient-derived HER2+ BBM1 tumor model we previously published in developing our HER2-CAR T cells23. Here, ERBB2 is linked to neoplasm.